Back

The role of SGLT2 inhibitors in patients without diabetes.

1 September 2020 (11:05 - 11:15)
Organised by:
Congress Presentation Part of: Managing Heart Failure in 2020 – Insights from the Experts Epidemiology, Prognosis, Outcome ESC Premium Access ESC Congress 2020

About the speaker

Photo
Associate Professor Kevin Damman

University Medical Centre Groningen, Groningen (Netherlands (The))

1 More presentation in this session

Presentation thumbnail
Left ventricular ejection fraction – The beauty and the beast of heart failure.
Professor S. Solomon (Boston, US)
Slides Video

Access the full session

Session thumbnail
Managing Heart Failure in 2020 – Insights from the Experts

The Event

Event poster

ESC Congress 2020

1 September 2020 11:05 CET
You may be interested in
thumbnail
Congress Presentation
Cardiovascular benefits of SGLT2i in type 2 diabetes without heart failure: a subgroup analysis
30 August 2025
thumbnail
Congress Session
Novel therapies in managing patients with cardiovascular-kidney-metabolic (CKM) syndrome and heart failure
4 April 2025
thumbnail
Congress Presentation
SGLT2 inhibitors for obesity
31 August 2024
thumbnail
Congress Session
The power of now: a focus on SGLT2 inhibitors for heart failure in the hospital
17 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources